Vioxx
Categoria
Vioxx Nombres de marca, Vioxx Analogos
Vioxx Marca los nombres de mezcla
Vioxx Formula quimica
C17H14O4S
Vioxx RX enlace
http://www.rxlist.com/cgi/generic/rofecox.htm
Vioxx FDA hoja
Vioxx MSDS (hoja de seguridad de materiales)
Vioxx Sintesis de referencia
No hay información disponible
Vioxx Peso molecular
314.357 g/mol
Vioxx Punto de fusion
No information avaliable
Vioxx H2O Solubilidad
Insoluble
Vioxx Estado
Solid
Vioxx LogP
3.019
Vioxx Formas de dosificacion
Tablet (12,5 mg, 25 mg o 50 mg), la suspensión oral (12,5 o 25 mg por ml de solución 5)
Vioxx Indicacion
Para el tratamiento de la osteoartritis, dolor agudo en adultos y el dolor menstrual.
Vioxx Farmacologia
Rofecoxib, un ciclooxigenasa-2 (COX-2) inhibidores, se clasifica como antiinflamatorios no esteroideos (AINE). Rofecoxib es utilizado por sus actividades anti-inflamatorias, analgésicas y antipiréticas en el manejo de la osteoartritis (OA) y para el tratamiento de la dismenorrea o dolor agudo. A diferencia de celecoxib, rofecoxib carece de una cadena sulfonamida y no requiere de enzimas del citocromo P450 para el metabolismo.
Vioxx Absorcion
La biodisponibilidad oral media de rofecoxib a dosis terapéuticamente recomendada de 12,5, 25 y 50 mg es aproximadamente del 93%.
Vioxx Toxicidad
No hay sobredosis de rofecoxib fueron reportados durante los ensayos clínicos. La administración de dosis únicas de rofecoxib de 1000 mg a 6 voluntarios sanos y en dosis múltiples de 250 mg / día durante 14 días a 75 voluntarios sanos no produjo toxicidad grave.
Vioxx Informacion de Pacientes
PATIENT INFORMATION
Physicians should instruct their patients to read the patient package insert before starting therapy with VIOXX and to reread
it each time the prescription is renewed in case any information has changed.
VIOXX can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in
hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms,
patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing
any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up. Risk of GI Ulceration, Bleeding
and Perforation. Patients should be informed that VIOXX is not a substitute for aspirin for cardiovascular prophylaxis because of
its lack of effect on platelets. For additional cardiovascular safety information see CLINICAL STUDIES, Special Studies, VIGOR and
PRECAUTIONS, Cardiovascular Effects.
Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain,
edema or chest pain to their physicians.
Physicians should instruct their patients to read the patient package insert before starting therapy with VIOXX and to reread
it each time the prescription is renewed in case any information has changed.
VIOXX can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in
hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms,
patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing
any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up. Risk of GI Ulceration, Bleeding
and Perforation. Patients should be informed that VIOXX is not a substitute for aspirin for cardiovascular prophylaxis because of
its lack of effect on platelets. For additional cardiovascular safety information see CLINICAL STUDIES, Special Studies, VIGOR and
PRECAUTIONS, Cardiovascular Effects.
Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain,
edema or chest pain to their physicians.
Vioxx Organismos afectados
Humanos y otros mamíferos
